191 related articles for article (PubMed ID: 17191752)
1. Survey on the safety of a no-updosing regimen of sublingual immunotherapy.
Musarra A; Cilia M; Pecora S; Passalacqua G
Eur Ann Allergy Clin Immunol; 2006 Nov; 38(9):313-4. PubMed ID: 17191752
[No Abstract] [Full Text] [Related]
2. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase.
Giordano T; Quarta C; Bruno ME; Falagiani P; Riva G
Eur Ann Allergy Clin Immunol; 2006 Nov; 38(9):310-2. PubMed ID: 17191751
[TBL] [Abstract][Full Text] [Related]
3. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children.
Dehlink E; Eiwegger T; Gerstmayr M; Kampl E; Bohle B; Chen KW; Vrtala S; Urbanek R; Szépfalusi Z
Clin Exp Allergy; 2006 Jan; 36(1):32-9. PubMed ID: 16393263
[TBL] [Abstract][Full Text] [Related]
4. Once daily sublingual immunotherapy without updosing--A new treatment schedule.
Rodriguez F; Boquete M; Ibáñez MD; de la Torre-Martínez F; Tabar AI
Int Arch Allergy Immunol; 2006; 140(4):321-6. PubMed ID: 16741368
[TBL] [Abstract][Full Text] [Related]
5. Randomized open comparison of the safety of SLIT in a no-updosing and traditional updosing schedule in patients with Parietaria allergy.
Guerra L; Compalati E; Rogkakou A; Pecora S; Passalacqua G; Canonica GW
Allergol Immunopathol (Madr); 2006; 34(2):82-3. PubMed ID: 16808019
[TBL] [Abstract][Full Text] [Related]
6. Observational study of the safety of an ultra-rush sublingual immunotherapy regimen to treat rhinitis due to house dust mites.
Roger A; Justicia JL; Navarro LÁ; Eseverri JL; Ferrès J; Malet A; Alvà V
Int Arch Allergy Immunol; 2011; 154(1):69-75. PubMed ID: 20664280
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled, trial.
La Grutta S; Arena A; D'Anneo WR; Gammeri E; Leonardi S; Trimarchi A; Platania D; La Rosa M
Eur Ann Allergy Clin Immunol; 2007 Feb; 39(2):40-4. PubMed ID: 17441414
[TBL] [Abstract][Full Text] [Related]
8. Sublingual specific immunotherapy reduces PBMC proliferations.
Fenoglio D; Puppo F; Cirillo I; Vizzaccaro A; Ferrera A; Tosca MA; Marseglia G; Ciprandi G
Eur Ann Allergy Clin Immunol; 2005 Apr; 37(4):147-51. PubMed ID: 15916016
[TBL] [Abstract][Full Text] [Related]
9. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and its persistence, in children and adults.
Di Rienzo V
Int J Immunopathol Pharmacol; 2005; 18(4 Suppl):35-7. PubMed ID: 17761106
[No Abstract] [Full Text] [Related]
11. LAIS - Posological schedules.
Bruno M
Int J Immunopathol Pharmacol; 2005; 18(4 Suppl):33-4. PubMed ID: 17761105
[No Abstract] [Full Text] [Related]
12. Oral reactions to sublingual immunotherapy: a bioptic study.
Marcucci F; Sensi L; Incorvaia C; Di Cara G; Moingeon P; Frati F
Allergy; 2007 Dec; 62(12):1475-7. PubMed ID: 17983387
[No Abstract] [Full Text] [Related]
13. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years.
Rienzo VD; Minelli M; Musarra A; Sambugaro R; Pecora S; Canonica WG; Passalacqua G
Clin Exp Allergy; 2005 May; 35(5):560-4. PubMed ID: 15898975
[TBL] [Abstract][Full Text] [Related]
14. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year).
Passalacqua G; Musarra A; Pecora S; Amoroso S; Antonicelli L; Cadario G; Di Gioacchino M; Lombardi C; Ridolo E; Sacerdoti G; Schiavino D; Senna G
Pediatr Allergy Immunol; 2007 Feb; 18(1):58-62. PubMed ID: 17295800
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis.
Tahamiler R; Saritzali G; Canakcioglu S
Laryngoscope; 2007 Jun; 117(6):965-9. PubMed ID: 17545861
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis.
Zhang L; Wang C; Han D; Wang X; Zhao Y; Liu J
Int Arch Allergy Immunol; 2009; 148(2):161-9. PubMed ID: 18802361
[TBL] [Abstract][Full Text] [Related]
17. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study.
Pajno GB; Caminiti L; Vita D; Barberio G; Salzano G; Lombardo F; Canonica GW; Passalacqua G
J Allergy Clin Immunol; 2007 Jul; 120(1):164-70. PubMed ID: 17543376
[TBL] [Abstract][Full Text] [Related]
18. [Sublingual vs subcutaneous immunotherapy].
Olivé Pérez A
Rev Alerg Mex; 2004; 51(1):29-35. PubMed ID: 15119753
[TBL] [Abstract][Full Text] [Related]
19. Physical exercise does not favour adverse reactions to allergen immunotherapy by the sublingual route.
Senna GE; Bonadonna P; Crivellaro MA; Incorvaia C; Sensi L; Frati F; Marcucci F
Eur Ann Allergy Clin Immunol; 2005 Feb; 37(2):58-9. PubMed ID: 15859363
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma.
Ozdemir C; Yazi D; Gocmen I; Yesil O; Aydogan M; Semic-Jusufagic A; Bahceciler NN; Barlan IB
Pediatr Allergy Immunol; 2007 Sep; 18(6):508-15. PubMed ID: 17680909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
